118 related articles for article (PubMed ID: 1419885)
1. Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors.
Toko T; Matsuo K; Shibata J; Wierzba K; Nukatsuka M; Takeda S; Yamada Y; Asao T; Hirose T; Sato B
J Steroid Biochem Mol Biol; 1992 Nov; 43(6):507-14. PubMed ID: 1419885
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
Toko T; Shibata J; Nukatsuka M; Yamada Y
Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
4. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.
Toko T; Sugimoto Y; Matsuo K; Yamasaki R; Takeda S; Wierzba K; Asao T; Yamada Y
Eur J Cancer; 1990 Mar; 26(3):397-404. PubMed ID: 2141500
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen.
Attardi B; Happe HK
Endocrinology; 1986 Aug; 119(2):904-15. PubMed ID: 3732150
[TBL] [Abstract][Full Text] [Related]
6. A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic mice.
Iino Y; Takai Y; Ando T; Ohwada S; Yokoe T; Sugamata N; Takei H; Horiguchi J; Iijima K; Morishita Y
Cancer Chemother Pharmacol; 1994; 34(5):372-6. PubMed ID: 8070003
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen.
Löser R; Seibel K; Roos W; Eppenberger U
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):985-90. PubMed ID: 4043181
[TBL] [Abstract][Full Text] [Related]
8. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
Catherino WH; Wolf DM; Jordan VC
Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.
Toko T; Shibata J; Sugimoto Y; Yamaya H; Yoshida M; Ogawa K; Matsushima E
Cancer Chemother Pharmacol; 1995; 37(1-2):7-13. PubMed ID: 7497599
[TBL] [Abstract][Full Text] [Related]
10. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
[TBL] [Abstract][Full Text] [Related]
11. Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59).
Shibata J; Toko T; Saito H; Lykkesfeldt AE; Fujioka A; Sato K; Hashimoto A; Wierzba K; Yamada Y
Cancer Chemother Pharmacol; 2000; 45(2):133-41. PubMed ID: 10663628
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
13. No loss of estrogenic or anti-estrogenic activity after demethylation of droloxifene (3-OH-tamoxifen).
Löser R; Seibel K; Eppenberger U
Int J Cancer; 1985 Dec; 36(6):701-3. PubMed ID: 4066073
[TBL] [Abstract][Full Text] [Related]
14. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
Coezy E; Borgna JL; Rochefort H
Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
[TBL] [Abstract][Full Text] [Related]
16. Differential impact of flanking sequences on estradiol- vs 4-hydroxytamoxifen-liganded estrogen receptor binding to estrogen responsive element DNA.
Anolik JH; Klinge CM; Bambara RA; Hilf R
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):713-30. PubMed ID: 8274405
[TBL] [Abstract][Full Text] [Related]
17. Rat uterine growth and induction of progesterone receptor without estrogen receptor translocation.
Jordan VC; Tate AC; Lyman SD; Gosden B; Wolf MF; Bain RR; Welshons WV
Endocrinology; 1985 May; 116(5):1845-57. PubMed ID: 3987619
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
19. Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor.
Garcia M; Derocq D; Platet N; Bonnet S; Brouillet JP; Touitou I; Rochefort H
J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):11-7. PubMed ID: 9328205
[TBL] [Abstract][Full Text] [Related]
20. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]